Tuesday 12 June 2018


Hello to all and welcome to my review. For those of you who don't know me yet, let me introduce myself. My name is Opeyemi and I'm an experienced writer who enjoys what he does very much. I'm here to give you all the information you might need or want about the newest company based in italy with the aim of  launching a Token Sale for supporting our AIDS, this Platform is definitely worth your time and therefore, mine, too. I plan to make them “easy read, to the point” because what's important to me is that we all comprehend and absorb the information and actually want to be here learning together about something new.


Innovative Bioresearch is a privately held biotech company based in Italy. Owned and founded by research scientist Jonathan Fior with the goal of bringing innovation to the field, with a focus on HIV, cancer and regeneration research. We are launching a Token Sale for supporting our AIDS (Acquired Immunodeficiency Syndrome associated with HIV infection) cure research, as well as to develop an application providing a on one hand a decentralized database for clinical data generated by our future human trials, to overcome the limitations of the current ancient centralized databases, and on the other hand a social platform for the HIV seropositive community and our future services. Let’s start by focusing on the first goal of this Token Sale, which is to support our AIDS cure research, with an overview of the current state of SupT1 cell infusion therapy, the novel cell-based therapy for HIV conceived by Jonathan Fior, owner and chief scientific officer of Innovative Bioresearch.

How Does Innovative Bioresearch Work? 
For research projects, Jonathan Fior works as PI (principal investigator), conceiving the experiments and writing the experiment protocol. The work is then commissioned to a Contract Research Organization (CRO), which physically performs the experiments. Jonathan Fior then supervises all aspects related to the research communicating closely with the CRO. Once the experiments are completed, he analyzes the results and writes a scientific paper, which is published in a peer reviewed scientific journal. This means that although our team is not a large team, we actually have companies with 100+ people working for us. This way we can keep a small, yet strong and great, team. We only publish on open access scientific journals as we believe in free information and don’t want our data being hidden behind a paywall.
One of our key objectives is to develop supine cell infusion therapy, our low cell-based therapy for HIV, to enable access to treatment for people who are usually left untreated due to social and / or economic limitations. There are 36.7 million people infected with HIV globally by 2016, 17.5 million are left untreated, according to unaids. We estimate our treatment to be cheaper than antiretroviral therapy (ART), which is conventional drug-based therapy for HIV, and substantially less expensive than gene therapy products that use modified autologous cells offered by our competitors. The social and economic impact of low cost HIV drug solutions such as supt1 cell infusion therapy will be enormous.We plan to use this app specifically for our AIDS healing research, to address the  limitations of the current centralized database. However, we believe there may be interest in using our apps by others. However, this will be an application designed by research scientists for research scientists. Our database will be open to any company or institution interested in using our application to store their clinical data. Moreover, we will encourage them to do so as we believe the scientific data should be publicly shared on our applications.
The main problem nowadays is a number of inconveniences in the centralized database that currently exists for clinical information. All data collected during medical research, combined into a single scientific paper which, once published in scientific journals, previously held a number of independent checks (also published in the NIH public data base). Once a new therapeutic strategy passes through all stages of clinical research, many research groups can begin experimenting. After final treatment approval, treatment can be prescribed directly for the patient.
All of this means that when the research team wants to conduct a specific clinical study, In fact, all patients have individual characteristics, so a personalized care protocol is required. A similar problem arises in the administration of approved treatment for the patient, therefore it is necessary through a large list of documentation to determine the correct treatment protocol. All this is not only a tedious process, but it can also cause human error factors.
Innovative Bioresearch proposes to solve such problems with access to clinical data by creating new decentralized databases based on block technology. All this will be done in a new app called "You're not alone". The application will be equipped with an easy-to-use interface that allows physicians to introduce various basic parameters for each patient (age, height, stage of disease, ethnic et al.), And outcomes of clinical treatment protocols.
Applications through access to all these data will do their development, statistical analysis and create a recommended care profile for each patient, thus eliminating the need to manually process large amounts of data, such as in a centralized clinical database that currently exists. "You are not alone" will also document all the progress of research projects on HIV and AIDS treatment, make systematic updates, publish articles. communities will be created, where HIV-positive people can communicate with each other, post comments and consult with experts, and all discussions will be under the supervision of group moderators. The application will also provide information on all modern clinical trials, how to participate in it, about the entire list of medical institutions.

To support research and application development, Innovative Bioresearch publishes its own currency, called INNBC. Tokens are based on the blockbuster Ethereum (ERC20), which shows a high level of reliable security and liquidity. The total number of INNBC tokens generated for the Hard Cup: 50 million, 100 million other tokens will be reserved exclusively for further economic support, and they will not be available for sale. Pre-ICO begins on May 1, 2018 (20 million INNBC-tokens are allocated). The main Token sales will be held in June (allocating approximately 30 million INNBC-tokens). Both stages will last 1.5 months.

ICOs are a very valuable tool for our society, but you have to carefully check that the project is legit before investing. We can tell you this about our project. We are a biotech company performing novel biomedical research, and scientific research is something serious. One of the things that sets our ICO apart from the other ICO offerings is that it is based on our AIDS cure research. Behind our project there are therefore many years of hard work and investments to perform and publish our research. Investors with us know that they are investing into something real and concrete, and not in one of those bubble soap projects that disappear the day after the ICO because they are not solving any real issue and are just a collection of fancy presentations. With us, investors can easily verify that our project is something real and legit by checking the publications on the NIH database pub med.
Token Name: INNBC
Platform: Ethereum
Type: ERC20
We have a hard cap of 50million INNBC. A 20million cap for the pre-sale, and a 30million cap for the sale.
We will use the additional funds to perform further clinical research (phase 4 trials) and we will also create a fund to provide our HIV treatment free of charge for patients who can't afford it.
We will organize a pre-ICO first. We will offer a 20% discount in the pre-sale (498INNBC per 1ETH), and a 10% discount in the successive sale (456INNBC per 1ETH). Regular emission price was set as 1EUR (1,23USD) per 1INNBC, corresponding to 415INNBC per 1ETH, with respect to the ETH/EUR exchange rate on the day of smart contract creation (16 April 2018).
Discount amount:
20% for Pre-ICO;
10% for the main Token Sales.
Minimum purchase size is 10 INNBC tokens.
Funds received after ICO will be distributed as follows:
50% of all funds will be spent on further research on AIDS treatment methods;
20% will be allocated for ecosystem development;
15% will be used to develop the application;
10% for stock JDM cars;
5% of the remaining funds will be used to maintain and maintain the application.
Access to use of INNBC tokens will be opened only after all crypto currencies have been sold out during ICO. Also, Innovative Bioresearch currency holders will be able to sell it to other users, thereby providing last access to the platform. Innovative Bioresearch wants to give all its investors something more, supporting INNBC-token values ​​also physically.

For more information, please visit:
Website : http://innovativebioresearch.com/
Whitepaper : https://goo.gl/yJhd87
Facebook : https://www.facebook.com/innovativebioresearch
Twitter : https://twitter.com/InnBioresearch
Telegram: https://t.me/innovativebioresearch
Ann Thread : https://bitcointalk.org/index.php?topic=3378302
YouTube: https://www.youtube.com/channel/UCbzc1KBQHAq4O7GzM-Jt6Lw
Bitcointalk profile link:https://bitcointalk.org/index.php?action=profile;u=1925101
ETH Address: 0x5B606c2F10687e77dc7Fe644E429320C6a39Df63
DISCLAIMER:This post was brought to you by Opeyemi being my personal project on INNBC campaign project

No comments:

Post a Comment